Medical technology firm Brainlab AG has asked for bank proposals for its potential initial public offering in Frankfurt, ...

Gareth McCartney, global co-head of equity capital markets at UBS, says the global IPO market is likely to see a resurgence in 2025, urging participants to "be ready and prepared." ...

Biotech firm Maze Therapeutics, backed by Third Rock Ventures, revealed a profit for the first nine months of 2024 in its ...

Simpson Thacher partners offer IPO tips for private companies, noting that having an independent board and the correct ...

The restaurant group announced Tuesday that Jose Alberto Dueñas is stepping down. Chief financial officer Paul Carbone, a ...

Nice One Beauty Digital Marketing Co. surged in its debut after a $320 million initial public offering in Riyadh, the latest ...

(Reuters) -Oilfield services provider Flowco Holdings on Tuesday said it is seeking a valuation of up to $2 billion in its ...

The share sale window of OrbiMed-backed Laxmi Dental will open on Monday, January 13, 2025, to raise Rs 698 crore and will ...

Just a month after announcing a $115 million series D financing to advance its lead assets, Maze Therapeutics is looking to ...

Drug developer Maze Therapeutics Inc.'s rollercoaster ride is leading to the Bay Area's first biotech IPO filing of 2025.

The fintech startup plans to use the newly introduced fast-track route to move its parent entity from the US to India.

The main difference between going public through an initial public offering (IPO) and staying private lies in ownership ...